Breast-Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application

Selective, sensitive, and specific breast cancer diagnosis: Neuropeptide Y (NPY) and the Y1R‐selective [Phe7, Pro34]NPY peptide were labeled with Re/99mTc and pre‐clinically characterized using competition receptor binding and signal transduction assays, and also microscopic, metabolic‐stability, ra...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie (International ed.) 2010-02, Vol.49 (6), p.1155-1158
Main Authors: Khan, Irfan U, Zwanziger, Denise, Böhme, Ilka, Javed, Muhammad, Naseer, Hamid, Hyder, Syed W, Beck-Sickinger, Annette G
Format: Article
Language:English
Subjects:
Animals
Breast Neoplasms - diagnosis
Cell Line, Tumor
Humans
Molecular Structure
neuropeptide Y
Neuropeptide Y - analogs & derivatives
Neuropeptide Y - chemical synthesis
Neuropeptide Y - pharmacokinetics
peptides
Rabbits
receptors
tumor diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Selective, sensitive, and specific breast cancer diagnosis: Neuropeptide Y (NPY) and the Y1R‐selective [Phe7, Pro34]NPY peptide were labeled with Re/99mTc and pre‐clinically characterized using competition receptor binding and signal transduction assays, and also microscopic, metabolic‐stability, rabbit body‐uptake, and protein‐binding studies. Selective uptake of the 99mTc(core)3+‐(NαHis‐ac)‐labeled [Phe7, Pro34]NPY analogue in human breast‐cancer patients was obtained by whole body scintimammography.
ISSN:1433-7851
1521-3773
DOI:10.1002/anie.200905008